The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
K Pharma is looking to leverage the logistics and supply-chain expertise of Alfresa Holdings as it advances KP8011, an iPS cell-derived regenerative medicine product for spinal cord injury, while continuing to fund long-term development through its parallel iPS-based drug discovery…
To read the full story
Related Article
- Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
November 7, 2025
- Alfresa Pharma Gets Japan Rights to Keio Biotech’s ALS Drug
March 3, 2023
BUSINESS
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
- Forxiga Generics Reach 11% Share in First Month: Intage
January 16, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…